• Synonyms：
  Maleimide-PEG-Amine HCl salt
  Mal-NH-PEG-NH2.HCl
  
• Purity：
  ≥95%
• Recommended Storage Condition：
  Store at -5°C,keep in dry and avoid sunlight.
• Uses：
  Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

Mal-PEG-NH₂·HCl is a linear heterobifunctional PEG derivative that contains a maleimide group on one end and an amino group on the other. As a versatile crosslinking reagent, it serves as an ideal PEG spacer for bioconjugation and surface modification. The maleimide group reacts specifically with thiol groups through Michael addition at pH 6.5–7.5 to form stable C–S bonds, while the terminal amine can couple with carboxylic acids or activated esters. Typically supplied as a hydrochloride salt for enhanced stability, Mal-PEG-NH₂·HCl is widely used in protein and peptide conjugation, drug delivery, and the synthesis of PEGylated block copolymers.

Cited Publications

This PEG derivative has been cited in peer-reviewed scientific publications. Browse the references below to learn more.

1. ​Lee, J. R., Kim, Y. M., Kim, E. J., Jang, M. K., & Park, S. C. (2024). Advancing Breast Cancer Therapeutics: Targeted Gene Delivery Systems Unveiling the Potential of Estrogen Receptor-Targeting Ligands. Biomaterials research, 28, 0087. https://doi.org/10.34133/bmr.0087 
2. Moura, R. P., Carvalho, E. D., Martins, C., Des Rieux, A., Pêgo, A. P., & Sarmento, B. (2023). Functionalized retinoic acid lipid nanocapsules promotes a two-front attack on inflammation and lack of demyelination on neurodegenerative disorders. Journal of Controlled Release, 358, 43-58. https://doi.org/10.1016/j.jconrel.2023.04.034  
3. Kim, J., Kim, J. S., Min, K. H., Kim, Y., & Chen, X. (2021). Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery. Bioengineering, 8(4), 43. https://doi.org/10.3390/bioengineering8040043 
4. Lourenço, B. N., Pereira, R. F., Barrias, C. C., Fischbach, C., Oliveira, C., & Granja, P. L. (2021). Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells. Nanomaterials, 11(2), 295. https://doi.org/10.3390/nano11020295 
5. Martins, C., Araújo, F., Gomes, M. J., Fernandes, C., Nunes, R., Li, W., Santos, H. A., Borges, F., & Sarmento, B. (2019). Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy. European Journal of Pharmaceutics and Biopharmaceutics, 138, 111-124. https://doi.org/10.1016/j.ejpb.2018.01.014

View more publications citing Biopharma PEG products.